Blood-camouflaged nanoparticles defeat drug-resistant breast tumors in mouse model
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15% to 20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with lim
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15% to 20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with lim This story matters for Science & Discovery readers tracking certification. Reported by phys.org. Read the full original at the source link below.
Originally reported by phys.org. CertificationNews.com curates and briefs the science & discovery stories that matter. Our editorial policy →
Get the daily certification signal